Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis

Abstract

IVB can achieve anatomical stabilisation of CNV secondary to SC, avoiding a decline in visual acuity, in almost 90% of cases over a 12-month follow-up.